@TumorBoardTues@JohnEbbenMDPhD#TumorBoardTuesday
📣Welcome as we summarize some of the incredible data from #ASCO23
👉There was SO much to take in, that even focusing on GI Cancers was a challenge
🙏As always, these were the🧑🏫that caught OUR interest, but this is not a judgement on those we do not highlight‼️
👉Last year, we saw the SEQUENCE data demonstrated a significant⬆️in mOS for #PancreaticCancer with alternating gem-nab and FOLFOX, compared to gem-nab alone👇
➡️@DrShubhamPant🗣️ an update on 57 Pts (21 w/ PDAC) Txed w/ the KRASG12C⛔️adagrasib
👉ORR 35% overall
👉N/V/D in ~50% of Pts - almost all Grade ≤2
👉6% Gr 3 fatigue
😀I am so excited to be at my 1⃣st IN PERSON ASCO GI in 3y
✅To prepare, I have gone through the abstract titles, and here are my Top GI ASCO 2023 abstracts
📣Disclaimer: There is no bias or exclusion intended.
These are just the ones I personally want to see👀
#GI23
➡️Starting with #Cholangiocarcinoma because it is a big year - especially because of:
✅SWOG 1815: A phase III trial of gem-cis-nab-pac vs. gem-cis as 1⃣st line💊for advanced BTC
👁️Rachna Shroff, Abs LBA490 @rachnatshroff
Again,🙏note - I went through a LOT of abstracts, and I definitely may have missed some‼️
👉And these are not in any particular order
✅But enjoy, RT, and reply😀
#ASCO22#PancreaticCancer
🤔Is more better❓
✅Dr. Carrato🧑🏫a Rand trial
👉Gem-nab-pac➡️FOLFOX (sequenced Q6 wks)
vs.
👉Standard Gem-nab-pac
➡️mOS was 3.5mos⬆️with sequenced Tx
➡️Even though more standard pts got 2nd line Tx
🤯Really❓
🤔Interesting
🔎GI Can Oral Abst 4022
#ASCO22#PancreaticCancer
🤔Is more better❓
✅Similarly, Dr. Portalesa🧑🏫a Rand Ph2 "Trial in Progress" comparing:
👉Sequential gem-nab-pac➡️FFX
vs.
👉Standard FFX alone
➡️Primary objective is OS
🤔But really, what will be critical will be the OS
🔎Abst TPS4190, Poster 160a
He was treated with every other week Gem-nab-pac
🙏@GIcancerDoc
➡️Had rapid symptomatic improvement
➡️Now essentially normal PS
➡️Nice response to treatment for 9 months🙂
➡️R-H Xu, et al (abstr 4000)
✅Ph 3 trial of camrelizumab plus chemo vs. chemo in patients with advanced esophageal SCC
👉Paclitaxel + cis +/- camrelizumab
👉596 patients randomized
🎉Camrelizumab plus chemotherapy⬆️mOS (15.3 vs. 12.0 mos) and ⬆️ORR (72.1% vs. 62.1%)
Alison M. Schram, @EileenMOReilly@graokane@benweinbergmd (abstr 3003)
➡️Zenocutuzumab (MCLA-128) in pancreas cancer and other solid tumors harboring NRG1 fusions